The End Of Small Molecule Drugs? Potential Implications Of US Price ‘Negotiation’

 
• By Michael McCaughan

The drug pricing provisions in the Build Back Better bill include a number of exemptions and protections – each of which could have interesting consequences for pharmaceutical development.

Sinking prescriptions
Will Build Back Better sink small molecule drugs? • Source: Nielsen Hobbs; the Pink Sheet |Alamy images

More from Pricing Debate

More from Market Access